Protagen Protein Services is pleased to inform you about our latest publication, an application note to: Advanced MS Approaches for the Characterization of ADC Heterogenity and Stability
created by Dr. Andreas Schummer, Dr. Jürgen Kast
Antibody-Drug conjugates (ADCs) are an emerging class of biotherapeutics that hold enormous promise for effective targeted therapy in oncology and beyond. They combine the strengths of antibodies and small molecule drugs - high specificity and high potency - in a single format.
Mass spectrometry (MS) is a powerful tool for the characterization of molecular details of large biomolecules. It is particularly useful for monitoring the attachment of linker/payload to an antibody and for assessing the stability of an ADC.
See also in Biopharmaceuticals: ADCs